Barclays has revised its outlook on Revvity (RVTY, Financial), reducing the company's price target from $140 to $110, while maintaining an Overweight rating on the stock. This adjustment comes as part of the bank's first-quarter earnings analysis for companies within the life science tools and diagnostics sector.
Analysts note that while the tools segment remains a defensive investment, its resilience is under pressure due to potential pharmaceutical-specific tariffs, which could lead to further budget cuts across the industry.
In addition to the Revvity update, Barclays also lowered its outlook on contract research organizations, citing reduced visibility in their operations. These changes reflect the shifting challenges and uncertainties affecting the broader life sciences market.
